News Releases

Date Title and Summary View
Aug 14, 2020
Aug 05, 2020
Johnson & Johnson Announces Agreement with U.S. Government for 100 Million Doses of Investigational COVID-19 Vaccine
Company working  to ensure broad global access to COVID-19 vaccine candidate, following approval from regulators NEW BRUNSWICK, N.J., Aug. 5, 2020 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) (the Company) today announced its Janssen Pharmaceutical Companies have entered into an agreement with
Aug 03, 2020
Jul 30, 2020
Jul 30, 2020
Single Dose of Johnson & Johnson COVID-19 Vaccine Candidate Demonstrates Robust Protection in Pre-clinical Studies
Study published in Nature shows J&J's investigational SARS-CoV-2 vaccine elicits a strong immune response that protects against subsequent infection   First-in-human Phase 1/2a clinical trial now underway in United States and Belgium; Phase 3 clinical trial expected to commence in September NEW
Jul 20, 2020
Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2020
NEW BRUNSWICK, N.J. , July 20, 2020 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the third quarter of 2020 of $1.01 per share on the company's common stock. The dividend is payable on September 8, 2020 to shareholders of
Jul 17, 2020
Jul 17, 2020
Jul 16, 2020
Johnson & Johnson Reports 2020 Second-Quarter Results:
- Sales of $18.3 billion reflecting a decline of 10.8%, operational decline of 9.0%* and adjusted operational decline of 8.8%*, primarily driven by the negative impact of the COVID-19 pandemic   - EPS of $1.36 decreased 34.6%; adjusted EPS of $1.67 decreased 35.3%*; 2019 included gain from sale of
Jul 14, 2020
This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.